In this context, the monoclonal antibody, Olamkicept (soluble gp130Fc or sgp130Fc), that specifically inhibits IL-6 trans-signaling without interfering with classic IL-6 signaling, is effective treatment for inflammatory bowel disease (IBD). This evidence concerns the gene IL6 and inflammatory bowel disease.